

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/574,575  
Applicant : Elena CONTI et al.  
Filed : April 20, 2007  
TC/A.U. : 1656  
Examiner : Suzanne Marie Noakes  
Docket No. : 2021-123  
Customer No. : 6449  
Confirmation No. : 9296

**RESPONSE TO OFFICE ACTION RESTRICTION REQUIREMENT**

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

In response to an Office Action restriction requirement dated March 20, 2009,  
Applicants elect Group IV, claim 9, with traverse. The restriction requirement is traversed  
on the basis of the following.

It is asserted in the Office Action that claim 5 (Group II) is anticipated by Kufer et al.  
Even if that is correct, without admitting same, at least the claims of Groups I and III share  
the same special technical feature with elected claim 9, i.e., the 3-dimensional structural  
information of the binding site of human TPX2 to phosphorylated human Aurora-A kinase.  
Moreover, as the subject matter of the claims of Group V is a result of performing the  
method of elected claim 9, Group V also shares the same special technical feature with  
elected claim 9.

Respectfully submitted,

By

  
George R. Repper  
Registration No. 31,414  
Attorney for Applicants  
1425 K Street, N.W., Suite 800  
Washington, D.C. 20005  
Telephone No.: (202) 783-6040  
Facsimile No.: (202) 783-6031